Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Transgelin-2 is a novel target of KRAS-ERK signaling involved in the development of pancreatic cancer

Fig. 5

S145 phosphorylation stabilizes transgelin-2 protein. a SW1990 cells were transfected with wild-type (W) or S145A (A) mutant of GFP-tagged transgelin-2 for 48 h. The cells were then treated with U0126 for additional 6 h. Transgelin-2 protein level was assessed by western blot. b. KRASG12D (KRAS) or vector control (CT) were co-transfected with wild-type (W) or S145A (A) mutant of GFP-tagged transgelin-2 into HPDE6-C7 cells for 48 h. Transgelin-2 protein level was assessed by western blot. c. SW1990 cells were transfected with wild-type of GFP-tagged transgelin-2 for 48 h. The cells were then treated with 100 μM MG132 and/or 15uM U0126 for 6 h. Transgelin-2 protein level was assessed by western blot. d. SW1990 cells were transfected with wild-type or S145A mutant of GFP-tagged transgelin-2 for 24 h. The cells were then treated with CHX for the indicated time points. Transgelin-2 protein level was assessed by western blot. Transgelin-2 level was expressed as percentage of starting level prior to CHX addition. *p < 0.05 compared with the wild-type group

Back to article page